Agenus Publishes Clinical Trial Titled ‘Balstilimab in Patients With Recurrent Cervical Cancer.’ To ClinicalTrials.Gov Site
https://clinicaltrials.gov/ct2/show/NCT04943627
50 Biggest Movers From Yesterday
Gainers
Verve Therapeutics, Inc. (NASDAQ: VERV) shares surged 68% to settle at $31.92 on Thursday after the company priced its IPO at $19 per share.
34 Stocks Moving In Thursday’s Mid-Day Session
Gainers
Cellect Biotechnology Ltd. (NASDAQ: APOP) shares jumped 68.5% to $5.51 after the company announced it filed a registration statement in connect with the proposed merger agreement with Quoin Pharmaceuticals.
Agenus Gains As Balstilimab US Application Accepted For Review In Cervical Cancer
The FDA has accepted for review Agenus Inc’s (NASDAQ:AGEN) marketing application seeking approval for balstilimab for recurrent or metastatic cervical cancer…
Agenus Says Co’s Presentations At ASCO 2021 ‘Demonstrate Differentiated Activity of Balstilimab and Provide Clinical Update on AGEN2373’
Agenus (NASDAQ:AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections,
The Week Ahead In Biotech: ASCO Presentations Front And Center, FDA Decisions Due For Scynexis, Liminal And Alkermes
After having declined through the first half of the week, biotech stocks staged a recovery to close higher in the trading week ended May 28. Broader market sentiment and company-specific news flow dictated stock moves during the week.
58 Biggest Movers From Yesterday
Gainers
BM Technologies, Inc. (NYSE: BMTX) shares climbed 26.4% to close at $11.82 on Tuesday after the company reported record Q1 results.
What’s Going On With Agenus Stock Today?
Agenus Inc (NASDAQ: AGEN) shares are trading higher by 35.28% at $4.41 Tuesday morning after the company, along with Bristol-Myers, announced an exclusive global license to Agenus' proprietary bispecific antibody program, AGEN1777.
Earnings Scheduled For May 6, 2021
Companies Reporting Before The Bell
• ViacomCBS (NASDAQ:VIAC) is projected to report quarterly earnings at $1.22 per share on revenue of $7.30 billion.